Next Article in Journal
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome
Previous Article in Journal
Repositioning the Sm-Binding Site in Saccharomyces cerevisiae Telomerase RNA Reveals RNP Organizational Flexibility and Sm-Directed 3′-End Formation
Previous Article in Special Issue
Small RNA Species and microRNA Profiles are Altered in Severe Asthma Nanovesicles from Broncho Alveolar Lavage and Associate with Impaired Lung Function and Inflammation
Open AccessReview

ncRNAs in Type-2 Immunity

Genentech Inc, South San Francisco, CA 94080, USA
*
Author to whom correspondence should be addressed.
Non-Coding RNA 2020, 6(1), 10; https://doi.org/10.3390/ncrna6010010
Received: 11 January 2020 / Revised: 26 February 2020 / Accepted: 27 February 2020 / Published: 6 March 2020
(This article belongs to the Special Issue Non-Coding RNA and the Immune System)
Immunological diseases, including asthma, autoimmunity and immunodeficiencies, affect a growing percentage of the population with significant unmet medical needs. As we slowly untangle and better appreciate these complex genetic and environment-influenced diseases, new therapeutically targetable pathways are emerging. Non-coding RNA species, which regulate epigenetic, transcriptional and translational responses are critical regulators of immune cell development, differentiation and effector function, and may represent one such new class of therapeutic targets. In this review we focus on type-2 immune responses, orchestrated by TH2 cell-derived cytokines, IL-4, IL-5 and IL-13, which stimulate a variety of immune and tissue responses- commonly referred to as type-2 immunity. Evolved to protect us from parasitic helminths, type-2 immune responses are observed in individuals with allergic diseases, including Asthma, atopic dermatitis and food allergy. A growing number of studies have identified the involvement of various RNA species, including microRNAs (miRNA) and long non-coding (lncRNA), in type-2 immune responses and in both clinical and pre-clinical disease settings. We highlight these recent findings, identify gaps in our understanding and provide a perspective on how our current understanding can be harnessed for novel treat opportunities to treat type-2 immune-mediated diseases. View Full-Text
Keywords: miRNA; LncRNA; helminth; allergy; IL-4; IL-13; TH2 miRNA; LncRNA; helminth; allergy; IL-4; IL-13; TH2
Show Figures

Figure 1

MDPI and ACS Style

Guidi, R.; Wedeles, C.J.; Wilson, M.S. ncRNAs in Type-2 Immunity. Non-Coding RNA 2020, 6, 10.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop